...
首页> 外文期刊>Annals of diagnostic pathology >CD133 expression in oral lichen planus correlated with the risk for progression to oral squamous cell carcinoma
【24h】

CD133 expression in oral lichen planus correlated with the risk for progression to oral squamous cell carcinoma

机译:口腔扁平苔藓中CD133表达与发展为口腔鳞状细胞癌的风险相关

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Oral lichen planus (OLP) is a potentially malignant disorder associated with an increased risk for progression to oral squamous cell carcinoma (OSCC). The objective of this study to determine protein expression of cancer stem cell marker CD133 in tissue samples of patients with OLP and evaluate the correlation between CD133 expression and the risk of progression to OSCC. In this longitudinal case-control study, a total of 110 patients with OLP who received a mean follow-up of 56 months were enrolled, including 100 patients who did not progress to OSCC and 10 patients who had progressed to OSCC. CD133 expression was determined using immunohistochemistry in samples from these patients. Analysis of 10 cases of normal oral mucosa and 6 cases of postmalignant OSCC form previously diagnosed OLP was also performed. The results showed that CD133 expression was observed in 29% cases of nonprogressing OLP and in 80% cases of progressing OLP (P =.002). CD133 was not expressed in normal oral mucosa, but it positively expressed in the 100% cases of OSCC. Logistic regression analysis revealed that the risk of malignant progression in the patients with CD133-positive expression was significantly higher than those with CD133 negativity (odds ratio, 9.79; 95% confidence interval, 1.96-48.92; P =.005). Collectively, CD133 expression was significantly associated with malignant progression in a longitudinal series of patients with OLP. Our findings suggested that CD133 may serve as a novel candidate biomarker for risk assessment of malignant potential of OLP.
机译:口腔扁平苔藓(OLP)是一种潜在的恶性疾病,与发展为口腔鳞状细胞癌(OSCC)的风险增加有关。这项研究的目的是确定癌症干细胞标志物CD133在OLP患者组织样本中的蛋白表达,并评估CD133表达与进展为OSCC风险之间的相关性。在这项纵向病例对照研究中,共纳入110名平均随访56个月的OLP患者,包括100例未进展为OSCC的患者和10例进展为OSCC的患者。使用免疫组织化学方法在这些患者的样本中确定CD133的表达。还对10例正常口腔粘膜和6例先前诊断为OLP的恶性后OSCC进行了分析。结果表明,在29%的非进行性OLP和80%的进行性OLP中观察到CD133表达(P = .002)。 CD133在正常口腔粘膜中不表达,但在100%的OSCC病例中阳性表达。 Logistic回归分析显示,具有CD133阳性表达的患者恶性进展的风险显着高于具有CD133阴性的患者(几率,9.79; 95%置信区间,1.96-48.92; P = .005)。集体地,在纵向系列的OLP患者中,CD133表达与恶性进展显着相关。我们的发现表明,CD133可以作为一种新的候选生物标志物,用于评估OLP恶性潜能的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号